Shares of Biogen Idec Inc. (NASDAQ:BIIB) closed the trading session at $102.15 below calculated support at $102.36 breaking the stock technically, raising concerns by investors, as the move might trigger more selling. Biogen Idec Inc. (NASDAQ:BIIB) develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The products from the biotechnology company addresses diseases such as multiple sclerosis, non-Hodgkin’s lymphoma, rheumatoid arthritis, crohn’s disease, and psoriasis.
